• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, April 1, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

A commonly offered add-on treatment for IVF fails to provide any benefit in a large randomized trial

Bioengineer by Bioengineer
July 3, 2018
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Barcelona, 3 July 2018: An add-on treatment commonly offered to female IVF patients to improve their chance of success has been shown in a large randomised trial to be of no value. "Endometrial scratch", a technique whereby a small scratch or tissue biopsy is made to the lining of the uterus prior to IVF, was associated with no improvements in pregnancy or live birth rates, and should, say an international team of investigators, be abandoned as a procedure by fertility clinics.

The results of the study are presented today in Barcelona at the 34th Annual Meeting of ESHRE by Dr Sarah Lensen, a researcher from the University of Auckland, New Zealand.

The study was a large randomised trial performed at 13 fertility centres in five countries (New Zealand, UK, Belgium, Sweden and Australia) and involving more than 1300 women having IVF. One half were randomly assigned to endometrial scratching and the other to no adjuvant procedure. The scratch was performed with a Pipelle cannula, a small flexible plastic tube commonly used for performing uterine biopsy for a variety of indications. In IVF, where some studies have shown a benefit in outcome, it's been proposed that injury to the lining of the uterus causes an inflammatory response conducive to implantation following embryo transfer.

"Results from earlier studies have suggested a benefit from endometrial scratching in IVF," explained Lensen, "especially in women with previous implantation failure. However, many of these studies had a high risk of bias in their design or conduct and did not provide strong evidence. There was still uncertainty about the validity of a beneficial effect."

Women in the endometrial scratch arm of the study had a Pipelle biopsy between day 3 of the preceding cycle and day 3 of the IVF/embryo transfer cycle. Controls had no intervention. Results showed that clinical pregnancy rate in the endometrial scratch group was 31.4% and in the control group 31.2%; live birth rates were 26.1% in the former and 26.1% in the latter. The probabilities of pregnancy were still comparable after controlling for variables and sub-group analysis, which included patients with a history of implantation failure in IVF (defined as two or more unsuccessful embryo transfers). This group in earlier studies has appeared to gain particular benefit from the procedure.

This latest study also measured pain discomfort score associated with endometrial scratch and found "a moderate amount of pain and bleeding". This too, said the investigators, was further reason why endometrial scratch should be abandoned and removed from the list of IVF adjuvant options.

Endometrial scratch is a reportedly common add-on treatment in fertility clinics. A survey of clinics in Australia, New Zealand and UK performed by Lensen and colleagues in 2016 found that 83% of clinicians would recommend endometrial scratching prior to IVF, especially to women with recurrent implantation failure.(1)

"Our results contradict those of many studies published previously," said Lensen, "and, although our trial was the largest and most robust study undertaken so far, it can be difficult for one trial to change practice. However, there are other trials under way at the moment, including two large studies from the Netherlands and UK. Nevertheless, even based just on our results, I think clinics should now reconsider offering endometrial scratch as an adjuvant treatment."

###

Abstract O-139, Tuesday 3 July 2018

Endometrial scratching by Pipelle biopsy in IVF (the PIP study): A pragmatic randomised controlled trial

Endometrial scratch: the story so far

1. See Lensen S, Sadler L, Farquhar C. Endometrial scratching for subfertility: everyone's doing it. Hum Reprod 2016; 31: 1241-1244.

2. Several (but not all) studies in the past reported a greater chance of pregnancy in women who had had some minor surgical procedure in the uterus, such as hysteroscopy (see for example, El Toukhy T, Sunkara SK, Coomarasamy A, et al. Outpatient hysteroscopy and subsequent IVF cycle outcome: a systematic review and meta-analysis. Reprod Biomed Online 2008; 16: 712-9.

3. This benefit was seen in a review of recent studies (of "intentional" endometrial injury) in women prior to IVF (see Nastri CO, Gibreel A, Raine-Fenning N, et al. Endometrial injury in women undergoing assisted reproductive techniques). However, conclusions were described as "uncertain".

4. Some studies have proposed that endometrial injury might help improve reproductive outcomes by increasing endometrial receptivity for an implanting embryo by the release of growth factors from the uterine tissue or by changes in its cell structure.

5. There are 20 or more randomised trials of endometrial injury published. What makes this more reliable than the others, says Sarah Lensen, is not that it had more reliable methods of randomisation, measured harms as well as benefit, and had a low risk of bias, but its large sample size – at 1300 it is far bigger than in any other trials published to date.

* When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.

For further information on the details of this press release, contact:

Christine Bauquis at ESHRE
Mobile: +32 (0)499 25 80 46
Email: [email protected]

Media Contact

Christine Bauquis
[email protected]
32-499-258-046
@ESHRE

https://www.eshre.eu/

Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Research on Adult Outcomes After Complex Perinatal History

April 1, 2026

Inequities in Family Engagement Within the NICU

April 1, 2026

Frailty, Malnutrition Link Falls to Daily Functioning

April 1, 2026

Dactylides D, E: Novel 22-Membered Polyol Macrolides

April 1, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1006 shares
    Share 398 Tweet 249
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Research on Adult Outcomes After Complex Perinatal History

Unveiling the Biological Pathways Linking Pesticides to Cancer Risk: New Study Sheds Light on Environmental Health Impacts

Inequities in Family Engagement Within the NICU

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.